Clik here to view.
Alembic Pharma advances 1% on Rhizen-Novartis license agreement
India Infoline News Service | Mumbai | December 10, 2015 11:32 IST Swiss subsidiary Rhizen Pharmaceuticals S.A. entered into an exclusive, worldwide license agreement with Novartis for the...
View ArticleClik here to view.
RP 6530, Rhizen Pharmaceuticals S.A. and Novartis tieup for Rhizen’s inhaled...
(A) and (Al) and (A2) (S)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (Compound A1 is RP 6530). RP...
View ArticleClik here to view.
TGR-1202, a Phosphoinositide-3 kinase delta inhibitor, Rhizen Pharmaceuticals...
TGR 1202, TGR-1202-101, RP 5264 AK173784; (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one...
View ArticleClik here to view.
MELOGLIPTIN
Melogliptin Phase III A DP-IV inhibitor potentially for treatment of type II diabetes. EMD-675992; GRC-8200 CAS No. 868771-57-7...
View ArticleClik here to view.
Ataciguat
Ataciguat HMR-1766 Hoechst Marion Roussel De Gmbh 5-Chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide C21H19Cl2N3O6S3 UNII-QP166M390Q; 576.49306 g/mol A...
View ArticleClik here to view.
Pranidipine
Pranidipine , OPC-13340, FRC 8411 Acalas® NDA Filing in Japan A calcium channel blocker potentially for the treatment of angina pectoris and hypertension. CAS No. 99522-79-9 Molecular...
View ArticleClik here to view.
FDA approves new oral therapy to treat ALK-positive lung cancer
FDA approves new oral therapy to treat ALK-positive lung cancer 12/11/2015 01:03 PM EST The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced...
View ArticleClik here to view.
FDA approves first emergency treatment for overdose of certain types of...
FDA approves first emergency treatment for overdose of certain types of chemotherapy 12/11/2015 12:05 PM EST The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the...
View ArticleClik here to view.
Lixivaptan
Lixivaptan CRTX-080; VPA-985; WAY-VPA-985 N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide...
View ArticleClik here to view.
TEVA’S CEP 1347, KT 7515 a MAP3K11 (MLK3) inhibitor potentially for the...
CEP-1347; KT-7515 CAS. 156177-65-0 Cephalon Inc, Kyowa Hakko Kogyo Kk WO2000013015 synthesis coming……....
View ArticleClik here to view.
PF-04191834 for Patients With Osteoarthritis Of The Knee
PF 4191834 CAS 1029317-21-2 UNII-YX55DXP4T1; PF-4191834; DVNQWYLVSNPCJZ-UHFFFAOYSA-N; 4-(3-{[4-(1-methyl-1H-pyrazol-5-yl)phenyl]thio]phenyl) tetrahydro-2H-pyran-4-carboxamide;...
View ArticleClik here to view.
RO-28-1675 for Type 2 Diabetes
RO-28-1675 (2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide Ro 028-1675 Ro 0281675 Ro 28-1675 3-Cyclopentyl-2(R)-[4-(methylsulfonyl)phenyl]-N-(2-thiazolyl)propionamide MW...
View ArticleClik here to view.
AN 2898
AN2898 (5-(3,4-dicyanophenoxy)-1-hydroxy -1,3-dihydro-2,1-benzoxaborole) 1,2-Benzenedicarbonitrile, 4-((1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy)-, AN-2898 cas: 906673-33-4 UNII: 6O60L94RMB,...
View ArticleClik here to view.
New Drug Approvals blog by Dr Anthony Crasto hits ten lakh views in 211...
New Drug Approvals hits ten lakh views in 211 countries http://newdrugapprovals.org/ THANKS AND REGARD’S DR ANTHONY MELVIN CRASTO Ph.D amcrasto@gmail.com MOBILE-+91 9323115463 GLENMARK...
View ArticleClik here to view.
FDA approves new orphan drug Uptravi (selexipag) to treat pulmonary arterial...
KEEPING WATCHING THIS POSTS FOR SYNTHESIS UPDATES FDA approves new orphan drug to treat pulmonary arterial hypertension 12/22/2015 On December 21, the U.S. Food and Drug Administration approved...
View ArticleClik here to view.
GS 9883, Bictegravir an HIV-1 integrase inhibitor
GS 9883, bictegravir CAS 1611493-60-7 PHASE 3 HIV-1 integrase inhibitor...
View ArticleClik here to view.
CE-224535 for the treatment of rheumatoid arthritis and osteoarthritis
CE-224535 2-(4-Chloro-3-(3-(1-hydroxycycloheptyl)propanoyl)phenyl)-4-((2R)-2-hydroxy-3-methoxy-propyl)-1,2,4-triazine-3,5-dione Benzamide,...
View ArticleClik here to view.
PNQ 370 useful in treating Parkinson’s disease from ADVINUS
PNQ 370 Advinus Therapeutics Ltd Adenosine A2a receptor antagonist for treating disease or disorder susceptible to improvement by antagonism of A2A receptor. Advinus Therapeutics is investigating...
View ArticleClik here to view.
PNQ 201 from Advinus for for potential treatment of IBD.
PNQ 201 STRUCTURE COMING…… Adenosine A2b receptor antagonist Advinus Therapeutics Ltd KEEP WATCHING THIS POST…………… PNQ-201 is a proprietary orally active A2B Adenosine receptor (A2BAdoR) antagonist,...
View ArticleClik here to view.
PNQ 103 from Advinus for the potential treatment of COPD & sickle cell...
PNQ 103 STRUCTURE COMING………… for the potential treatment of COPD & sickle cell disease (SCD) Adenosine A2b receptor antagonist Advinus Therapeutics Ltd KEEP WATCHING THIS POST………. PNQ-103 is a...
View Article